We report a 55-year-old man who showed no change after chemotherapy for chronic myelogenous leukemiablastic crisis (CML-BC) in 1998. Allo-peripheral blood stem cell transplantation (PBSCT) was then performed and Complete remission ( 
Introduction
Recently the BCR-ABL-specific tyrosine kinase inhibitor, imatinib, has been showing extremely high therapeutic effectiveness against chronic myelogenous leukemia in the chronic stage (1, 2) , but no such therapeutic effect can realistically be expected in cases of blastic crisis (3) , and thus stem cell allografting is necessary. However, we encountered a case in which complete remission occurred using imatinib as pretreatment.
Case Report
A 55-year-old man presented with malaise in April 1998, and the following month his physician detected anemia and thrombocytopenia. The patient was referred to our hospital for testing on June 15, 1998, when CML-BC (mixed lineage type Ph1+) in the bone marrow (BM) was diagnosed. Chemotherapy was performed, but the result was no response. On April 21, 1999, the patient underwent allo-PBSCT, resulting in complete remission (CR). Thereafter, interstitial pneumonia and cellulitis developed and the subject was again admitted for treatment and discharged. He was followed thereafter as an outpatient and CR was maintained. However, thrombocytopenia gradually became evident from September 2001, and on December 21 a number of blasts were seen in the BM and a relapse was confirmed. The following day he was hospitalized for treatment.
The patient measured 174 cm in height and weighed 71 kg. His body temperature was 36.7°C, pulse 86/min and regular, and blood pressure 152/92 mmHg. The patient was lucid, there was no anemia or jaundice, and no heart murmur. Respiration sounds were normal, and there were no abnormal abdominal findings (no splenomegaly). Superficial lymph nodes were not palpable and there were no abnormal neurological findings.
Laboratory examination on admission revealed that there was no anemia and the white blood cell count was also normal. There was no increase in eosinophil number. Blasts were seen in peripheral blood (Table 1) , and bone marrow images showed that overall there was hyperplasia. Karyotypes were asymmetrical and 88.2% of blasts had two or three nucleoli. The cell surface markers showed positive reactions for CD2, CD7, CD13, CD19 and HLA-DR (Fig. 1) . Chromosome testing revealed translocation between chromosome 9 and chromosome 22, the so-called Philadelphia chro-mosome (Fig. 2) . Genetic testing using FISH revealed a high BCR-ABL blending signal positivity rate of 92.2%.
Administration of 600 mg daily imatinib was started on December 22 after hospitalization. However, thrombocytopenia and leukopenia were evident and hypoplasia occurred in the bone marrow, so the dose was reduced to 300 mg from January 20, 2002. However, bone marrow hypoplasia progressed so the drug was withdrawn on February 4. Thereafter, the blast count increased and the patient was re-started on 300 mg on March 6. On March 20 blast percentage in BM was 3.6% so PR was diagnosed. The patient was discharged, but RIST was considered necessary so he was re-admitted on May 7. We selected a matching sibling (younger brother) the same donor as the previous transplantation, because we could not find another matching donor.
The donor was a 50-year-old man. For PBSCH we induced stem cells in peripheral blood by Lenograstim (500 g/day) for 5 days and collected CD34 positive cells 2 times. As a result, we collected 7.7×10 8 revealed no increase in blasts and the bone marrow was normal, so it was judged the patient had undergone a complete hematological remission (Fig. 4) . Chromosome testing also confirmed there was no Ph1 chromosome (Fig. 5) , and genetic testing showed no BCR-ABL blending signals, so a cytogenetically complete remission was judged to have occurred. The patient is currently being followed as an outpatient with cytogenetically complete remission maintained for 1 year.
Discussion
CML is caused by BCR-ABL-specific tyrosine kinase produced by the Philadelphia (Ph) chromosome. Imatinib is a selective inhibitor of tyrosine kinase. Since clinical trials were started on Interferon (IFN) therapy-resistant chronic stage CML patients in the US in June 1998, better than expected effects have been shown in not only the chronic stage but also the transition and acute stages of this disease (4, 5) . The effects exceeded those of IFN, which has to date been the principal therapeutic drug (1, 2) , and imatinib has become the primary drug of choice in chronic stage CML. With respect to the therapeutic effects of imatinib alone, as shown in Table 2 , it has good therapeutic effects in the chronic stage, with remission rates rising as high as 95%, but not even a hematological effect can be expected in the blast phase (1, 5-7) . Also, the recurrence rate is high even among those who have entered remission, and the mean number of survival years is no more than one year (3). That is why, conventionally, stem cell allografting or therapy based on acute myelogenous leukemia (AML) has been performed for cases of blastic crisis. By no means, however, have the results been positive.
We therefore compared the rates of survival after transplantation according to the pre-transplantation condition in CML. As shown in Table 3 , this revealed that good survival could not really be expected when the blastic crisis had not been pre-treated (8) . However, high survival rates could be expected for transplantation after remission or after a return to the chronic stage. Although the effect of imatinib alone was by no means significant against cases of CML blastic crisis, it is considered valid to use imatinib as a pre-treatment for transplantation with the aim of achieving a certain level of hematological effect, rather than perform the transplantation straight away. The present patient experienced complete remission after PR with imatinib and then RIST, and we consider that his condition prior to transplantation held the key to the clinical effectiveness.
In the present case, myeloablative stem cell transplantation had previously been conducted and the fact that the patient was elderly and with liver injury, so RIST was selected as the method of transplantation. It is possible that the graft versus leukemia effect was obtained due to this therapy. Thus, therapy by allograft after a patient has entered hematological remission is a new way of dealing with cases of CML-blastic crisis. and complete remission after RIST. This case is reported because the therapeutic strategy may present a new way of using imatinib for CML-blastic crisis.
Conclusion

